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Abstract Patients with diabetes caused by single-gene
mutations generally exhibit an altered course of diabetes.
Those with mutations of the glucokinase gene (GCK-MODY)
show good metabolic control and low risk of cardiovascular
complications despite paradoxically lowered high-density
lipoprotein (HDL) cholesterol levels. In order to investigate
the matter, we analyzed the composition of low-density
lipoprotein (LDL) and HDL subpopulations in such individ-
uals. The LipoPrint system (Quantimetrix, USA) based on
non-denaturing, linear polyacrylamide gel electrophoresis
was used to separate and measure LDL and HDL subclasses in
fresh-frozen serum samples from patients with mutations of
glucokinase or HNF1A, type 1 diabetes (T1DM) and healthy
controls. Fresh serum samples from a total of 37 monogenic
diabetes patients (21 from GCK-MODY and 16 from HNF1A-
MODY), 22 T1DM patients and 15 healthy individuals were
measured in this study. Concentrations of the small, highly
atherogenic LDL subpopulation were similar among the
compared groups. Large HDL percentage was significantly
higher in GCK-MODY than in control (p = 0.0003), T1DM
(p = 0.0006) and HNF1A-MODY groups (p = 0.0246).
Patients with GCK-MODY were characterized by signifi-
cantly lower intermediate HDL levels than controls
(p = 0.0003) and T1DM (p = 0.0005). Small, potentially
atherogenic HDL content differed significantly with the GCK-
MODY group showing concentrations of that subfraction
from control (p = 0.0096), T1DM (p = 0.0193) and HNF1A-
MODY (p = 0.0057) groups. Within-group heterogeneity
suggested the existence of potential gene–gene or gene–
environment interactions. GCK-MODY is characterized by a
strongly protective profile of HDL cholesterol subpopula-
tions. A degree of heterogeneity within the groups suggests the
existence of interactions with other genetic or clinical factors.
Keywords MODY  Monogenic diabetes  Lipid
subpopulations
Introduction
Although dyslipidemia is considered as a traditional risk
component for the metabolic syndrome, its qualitative
aspects, genetically determined subfractions and variation
in proatherogenic tendency have generated renewed inter-
est and debate [1]. Different cholesterol concentrations
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were reported in diabetes caused by single-gene mutations
in children and young adults [2, 3]. These studies reported
differences in apolipoprotein and HDL (high-density lipo-
protein) cholesterol levels. However, patients with diabetes
caused by mutations of the glucokinase gene (GCK-
MODY), who generally do not experience increased risk of
cardiovascular (CV) events despite being diagnosed with
diabetes, were shown to have lower levels of HDL than
healthy controls [3]. This somewhat counterintuitive
observation leads us to investigate the detailed composition
of low-density lipoprotein (LDL) and HDL subpopulations
in sera of adolescents and young adults with diabetes of
autoimmune and monogenic background. A potential
explanation would be that there are quantitative differences
in the composition of lipid subfractions as was previously
shown in the case of HNF1A-MODY and T2DM [2]. Since
it is recommended that the patients with GCK-MODY
should be treated with lifestyle modification and diet only,
it is important to give an additional evidence that these
diabetic patients are not at risk for CV complications.
Should patients with GCK-MODY exhibit an altered
composition of lipid subfractions, one may speculate that
some of them would be candidates for the use of lipid-
lowering agents.
Methods
Recruitment
The control group composed of young adults was selected
from among healthy, non-obese parents of children treated
for non-serious upper respiratory tract infections. Recruit-
ment of the control group and all laboratory analyses were
performed in the period of August 2012 to February 2013.
The GCK-MODY group was selected from the nationwide
database of the Polish Registry for Monogenic Diabetes
[4]. Fresh samples were obtained from patients from pre-
viously reported patients with GCK-MODY [5, 6] at
diagnostic or follow-up visits scheduled during the study
period and were stored in -80 C until analysis. The T1DM
group was planned to match the size of the GCK-MODY
group and was recruited from among the previously
reported patients, with their samples collected during fol-
low-up visits between August 2012 and February 2013 [7].
Patients with HNF1A-MODY were recruited by the
Department of Metabolic Disorders in Cracow from indi-
viduals recruited during earlier studies [8]. The sample size
of the MODY groups was determined by the availability of
samples that were frozen directly after serum separation
and did not undergo any freeze–thaw cycles to avoid decay
of lipid subpopulations. The study was performed in
accordance with the ethical standards of the responsible
committee on human experimentation (institutional and
national) and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. All patients gave their written
consent for participation in the project, and its protocol has
been approved by the Institutional Bioethics Committee of
the Medical University of Lodz.
Lipid assays
All study individuals were instructed to fast at least 8 h prior
to lipid profile assessment. Serum samples used in the study
were frozen immediately after centrifugation and shipped
with dry ice to the laboratory in Palermo (Italy). Non-dena-
turing, linear polyacrylamide gel electrophoresis was used to
separate and measure LDL subclasses, with the LipoPrint
system (Quantimetrix Corporation, Redondo Beach, CA,
USA) [9]. From each serum sample, 25 ll was taken to be
mixed with 200 ll (for LDL, IDL and VLDL) or 300 ll (for
HDL) of LipoPrint loading gel and loaded on the upper part
of the 3 % polyacrylamide gel. After 30 min of photopoly-
merization at room temperature, electrophoresis was per-
formed for 60 (LDL) or 50 (HDL) min at 3 mA. Each
electrophoresis chamber included two quality controls. After
scanning, electrophoretic mobility and the area under the
curve were calculated qualitatively and quantitatively. The
digital image is analyzed using software provided by the
producer—its computational algorithm program calculates
the cholesterol level for each of the lipoprotein fractions and
subfractions on the basis of area under the curve measure-
ment for each of the separated fractions, as performed in
other studies using the LipoPrint assay [2, 10]. LDL sub-
classes were distributed as seven bands: LDL-1 and LDL-2
defined as large LDL and LDL-3 to LDL-7 defined as small
LDL [11]. HDL subpopulations were distributed as ten
bands: HDL-1, HDL-2 and HDL-3 defined as large HDL;
HDL-4, HDL-5, HDL-6 and HDL-7 defined as intermediate
HDL; HDL-8, HDL-9 and HDL-10 comprising the small
HDL portion [12]. The cholesterol concentration of each of
the VLDL, IDL, LDL and HDL subpopulations was deter-
mined by multiplying the relative area under the curve of
each band by respective lipoprotein concentration.
Analysis of variance of log-transformed cholesterol sub-
population concentrations (ANOVA) was used in univariate
comparisons. Due to the expected differences in cholesterol
and triglyceride concentrations across the groups, we used %
content of each of the subpopulations for standardized profile
assessment across the compared groups. General linear
regression models were used to compare lipid subpopulation
levels after adjustment for age, sex and body mass index
(BMI). Post hoc testing was performed using the Tukey’s
HSD test [13]. p values lower than 0.05 were considered as
statistically significant. Statistical analysis was conducted
using Statistica 10.0 software (StatSoft, Tulsa, OK, USA).
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Results
Overall, we were able to obtain 42 fresh serum samples
from patients with monogenic diabetes: 22 from GCK-
MODY and 16 from HNF1A-MODY groups. A group of
22 eligible individuals with T1DM and 15 healthy indi-
viduals agreed to undergo the lipid profiling experiment.
One serum sample from the GCK-MODY group had to be
discarded due to hemolysis, leaving a final sample size of
79 patients. The studied group characteristics are provided
in Table 1.
After adjustment for sex distribution, age at examination
and BMI, significant differences between respective groups
were noted in levels of very-low-density lipoprotein (VLDL),
intermediate-density lipoproteins (IDL)-C and IDL-B, large
LDL and all three HDL fractions (Table 1). Patients with
GCK-MODY exhibited significantly higher VLDL levels
than controls (p = 0.0004). VLDL levels in controls were
also lower than in T1DM (p = 0.0283). Patients with
GCK-MODY had higher IDL-C levels than control
(p = 0.0002), T1DM (p = 0.0002) and HNF1A-MODY
groups (p = 0.0044). IDL-B levels did not show significant
differences in post hoc comparisons between any of the ana-
lyzed groups. Levels of the large LDL subpopulation were
lower in both GCK- and HNF1A-MODY groups than in
controls (p = 0.0002 and 0.0002, respectively) and T1DM
(p = 0.0002 and p = 0.0010, respectively). Levels of the
highly atherogenic small LDL subpopulation were similar
among the compared groups (Fig. 1a). Large HDL percentage
was significantly higher in GCK-MODY than in control
(p = 0.0003), T1DM (p = 0.0006) and HNF1A-MODY
groups (p = 0.0246). Patients with GCK-MODY were char-
acterized by significantly lower intermediate HDL levels than
controls (p = 0.0003) and T1DM (p = 0.0005). Small HDL
content differed significantly between the groups, with the
GCK-MODY group shown to have lower levels of this sub-
fraction from the control (p = 0.0096), T1DM (p = 0.0193)
and HNF1A-MODY groups (p = 0.0057) (Fig. 1b).
The patients age was not associated with significant
changes in either the most atherogenic small LDL
(r = -0.1339, p = 0.2803) or HDL (r = 0.0414,
p = 0.7404) fractions. Profile analysis by hierarchical clus-
tering showed evident heterogeneity despite statistically
significant differences between the groups. Among patients
with GCK- or HNF1A-MODY, nine individuals in both
groups showed considerable similarities of their lipid profile,
suggesting the existence of a MODY-specific effect (Fig. 2).
In-depth analysis of patients with GCK-MODY showed that
patients with identical mutations clustered more tightly
together than individuals with other types of GCK gene
alterations (Fig. 3). However, considerable variability was
noted between patients with GCK-MODY, suggesting that
the clinical phenotype of GCK-MODY may be strongly
modulated also by other genetic or environmental factors.
The observed differences of lipid profiles were not
associated with method of treatment, sex, age or diabetes
duration. Glycated hemoglobin levels did not correlate
significantly with lipid subpopulation percentages in the
whole studied group (all -0.25 \ r\ 0.25 with p [ 0.15).
Among patients with type 1 diabetes, HbA1c levels showed
non-significant correlations with small LDL and small
HDL levels (r = 0.46, p = 0.08 and r = 0.48, p = 0.07,
respectively). This lack of association may have been
caused by good metabolic control in the whole studied
group and small sample size of the subgroups with the
poorest metabolic control.
Discussion
Results of our study showed that individuals with GCK-
MODY exhibit a strongly protective profile HDL choles-
terol (high concentration of large HDL and low levels of
Fig. 1 VLDL, IDL, LDL (a) and HDL (b) subpopulations in
different types of diabetes. GCK glucokinase, HNF1A hepatocyte
nuclear factor-1 alpha, MODY maturity onset diabetes of the young,
T1DM type 1 diabetes
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intermediate and small HDL subpopulation) and provide a
reference material for further studies on the subject. While
constitutively moderately elevated glycemia observed in
these patients probably is a major factor contributing to the
low frequency of CV complications [14], the observed lipid
profile may also be important. The observed lack of cor-
relation of diabetes duration with profiles of the athero-
genic LDL and HDL subpopulations, in combination with
the non-progressive phenotype of GCK-MODY, supports
the hypothesis of a disease-specific profile of serum lipids.
Similarities noted among HNF1A-MODY also showed that
the presence of a major genetic determinant of disease (a
dominant mutation in case of MODY) may exert a strong
effect on the lipid profile and contribute indirectly toward
an altered risk of CV complications.
The degree of variability of lipid profiles among indi-
viduals with monogenic diabetes was considerable as evi-
denced by the incomplete clustering of particular groups
(Figs. 2, 3). Given the presence of a strong genetic modifier
responsible for the development of diabetes, this may seem
somewhat surprising as the phenotypical profile was
expected to be more uniform within the groups. However,
in view of earlier reports about the interactions between
common genetic variants and pathogenic mutations in
GCK-MODY [15], a similar effect could well be the reason
behind this heterogeneity. Such effects could be dependent
on polymorphic variants of GCKR or G6PC2 genes, both
of which were shown to affect lipid and glucose metabo-
lism [16]. However, given the abundance of clinical and
genetic factors affecting cholesterol level, further large-
scale studies supported by functional in vitro analyses are
necessary to identify major contributors.
Although the study does not definitely resolve the issue
of all possible alterations of lipid profile among patients
with monogenic diabetes, it does contribute to the field of
atherogenicity as the first report to show cardioprotective
HDL subpopulation profiles in young adults with GCK-
MODY. This group also exhibited lower concentrations of
LDL and elevated VLDL in comparison with healthy
controls and T1DM. As this may seem to be atherogenic,
since large LDLs are generally considered as neutral or
even protective [17], further studies into the LDL/HDL
profile discrepancies are necessary to quantify the relative
effects of either cholesterol type and their respective sub-
populations. However, it was already reported that the Lp
(a) lipoprotein, which is a known CV risk factor, is asso-
ciated with LDL-2 levels, which were categorized as large
LDLs in our analyses and were in fact shown to be present
Fig. 2 Hierarchical clustering plot of lipid profiles. Lipid subfraction
levels were standardized across the samples, and Euclidean distance
was used to visualize within- and between-group differences.
Although the lipid profiles of the majority of patients from the
HNF1A- and GCK-MODY groups showed within-group similarities,
considerable heterogeneity is evident, which suggests an overlapping
effect of environmental and/or other genetic factors
Fig. 3 Hierarchical clustering of lipid profiles of patients diagnosed
with GCK-MODY. Two mutations were present in more than one
individual: R43C and V302L. In both cases, in carriers of such
mutations similarities between lipid subfraction profiles were noted,
suggesting a strong, mutation-specific effect
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in significantly lower concentrations in patients with GCK-
MODY group than in other studied groups [18].
We were, however, unable to avoid some limitations.
Most importantly, the number of available patients was
associated with a rigorous sample collection program
introduced to avoid any methodological bias that would be
introduced by repeated freezing and thawing of the sera [19].
In contrast to earlier studies investigating atherogenicity, we
did not evaluate C-reactive protein (CRP) levels [20]. This
was considered as unnecessary, as patients with HNF1A-
MODY were previously reported to exhibit CRP levels near
detection limit, while GCK-MODY or T1DM patients do not
differ in that respect [21]. A similar rationale was behind our
decision of not testing apolipoprotein M (ApoM) level.
Patients with HNF1A-MODY were reported to have lower
levels of ApoM, than those with T1DM [22] and similar to
non-diabetic controls. As the diagnostic utility of the above
markers, and according to a recent paper by Steele et al. [23]
HbA1c as well, is sufficient in terms of discriminating
between particular types of monogenic diabetes, we did not
attempt to evaluate lipid subfractions as diagnostic tools or
compare them with these markers but rather to ascertain the
potential for atherogenic lipid profiles of the patients’ sera.
Impaired metabolic control could be another factor pro-
moting dyslipidemia, but as the studied group was generally
very well controlled in terms of HbA1c levels (median 6.5;
25–75 %, 5.95–7.55 %), it was impossible to precisely
analyze or adjust for this factor without serial measurements
or a group of individuals with worse metabolic control.
Although some patients with monogenic diabetes caused by
HNF1A or GCK mutations may show poor metabolic con-
trol, this is usually due to comorbidity with type 1 or type 2
diabetes [23, 24], making it impossible to study the impact of
high HbA1c in ‘‘pure’’ monogenic diabetes.
It is a generally accepted fact that patients with GCK-
MODY have lower triglyceride levels than controls and
patients with other causes of diabetes [3, 25, 26]. It seemed
possible that in some patients with GCK-MODY, high levels
of triglycerides were related to hyperglycemia at the time of
blood withdrawal, but none of the studied patients exhibited
signs of ketoacidosis. Moreover, their HbA1c levels mea-
sured during the study, as well on the next follow-up (data not
shown), did not hint at any evidence of a hyperglycemic
episode. Unfortunately, we were unable to measure blood
glucose levels to ascertain whether elevated blood glucose
was the reason for unusually high triglyceride concentrations
among patients with GCK-MODY. It is, however, now
known that metabolic control in GCK-MODY is remarkably
stable, regardless of treatment [27]. These considerations
lead us to conclude that the possibility of a hyperglycemic
cause of high triglycerides in our group was highly unlikely,
suggesting a different cause of hypertriglyceridemia present
in a small subset of patients with GCK-MODY.
Heterogeneity of lipid profiles among individuals with
different types of monogenic diabetes was not associated
with the type of treatment or any discernible clinical pat-
tern. This suggests that an overlap of major genetic factors
and common variants may have been in order, similarly as
was the case for metabolic control in GCK-MODY indi-
viduals [15]. One could also speculate that the observed
differences may be method-specific, as we performed the
analysis using the LipoPrint electrophoresis-based assay.
However, this technique was selected as it was shown to
provide accurate results, was validated against NMR
spectroscopy and other electrophoretic measurements [9,
28] and is less cumbersome in terms of application.
Unfortunately, the heterogeneity of lipid subpopulation
assessment methods makes it difficult to perform pooled
analyses as discrimination between the different subpopu-
lation levels may vary depending on the methodology used
in particular studies, which has resulted in a number of
seemingly conflicting reports on the role of specific sub-
populations of HDL on the risk of CV events [29].
Other limitations arose from the distributed, multicenter
nature of the monogenic diabetes registry study. We were
unable to evaluate the patients uniformly in terms of cardio-
vascular risk scores by measuring coronary artery calcification
(CAC) or evaluating other risk factors in a standardized
manner. We are aware that calcification of coronary arteries
was already shown to be frequent in patients with type 1
diabetes, although studies that focus on the subject generally
cover patients with worse metabolic control and long-lasting
diabetes [30, 31]. In our group, patients with monogenic
diabetes had very short duration of diabetes and all groups
showed low HbA1c levels, but we cannot exclude that some of
them may in fact have had higher CAC scores. All studied
patients were reportedly non-smokers, and none of them have
experienced any cardiovascular events and were not using any
lipid-lowering agents at the time of sample collection.
Another source of bias could be a different duration of sample
storage, as even in temperatures of -70 C were reported as
likely to exert an impact on HDL level [32]. Even though this
did not corroborate with other studies on the matter [33], we
were aware that storage duration and conditions might have
been a factor affecting the analysis. To correct for this par-
ticular effect, data were analyzed as relative values against
total concentrations of high- or low-density lipoproteins. It is
possible that non-identical decay rates could thus affect the
resultant profiles. However, given that the most significant
differences were noted between the GCK-MODY and the
T1DM and control groups, we did not consider this as a major
cause of the observed differences, as short-term storage was
shown not to affect the results of the Quantimetrix LipoPrint
assay [9].
The final hypothesis generated by the results shown in
this paper may be related to the emerging group of drugs
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termed as glucokinase activators. Since activation of glu-
cokinase through the GCKR was reported to elevate tri-
glyceride levels [34], one can expect that stimulation of
glucokinase with pharmacological agents may alter the
lipid profile in diabetic patients. Elevation of triglycerides
was recently observed in an experimental study on mice
treated with two glucokinase-activating compounds [35].
Although at this stage such effects in humans are difficult
to foresee, the impact of drugs acting through glucokinase-
dependent mechanisms warrants further investigation for
adverse effects promoting the atherogenic process.
Conclusions
GCK-MODY is characterized by strongly protective profile
of HDL cholesterol subpopulations. A degree of hetero-
geneity within the groups suggests the existence of inter-
actions with other genetic or clinical factors affecting the
phenotype.
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